产品详情
靶点信息
VEGFR2 | Flk1 | FGFR1 | VEGFR1 | |
25 nM | 89 nM | 148 nM | 380 nM |
In vitro (25°C) | DMSO | 83 mg/mL (188 mM) | |
Water | Insoluble | ||
Ethanol | 83 mg/mL (188 mM) | ||
In vivo | 0.5% methylcellulose+0.2% Tween 80 | 9 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 22.65 mL | 113.25 mL | 226.5 mL |
0.5 mM | 4.53 mL | 22.65 mL | 45.3 mL |
1 mM | 2.27 mL | 11.33 mL | 22.65 mL |
5 mM | 0.45 mL | 2.27 mL | 4.53 mL |
*The above data is based on the productmolecular weight 441.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10162 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 441.5 |
Formula | C22H24FN5O4 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 649735-63-7 |
Synonyms | BMS582664 |
SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C |
产品资料
产品标签
Product Questions
Product Questions
RAF265 (CHIR-265)
RAF265 (CHIR-265)是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,可控制或正常化VEGFR-2,同时抑制B-raf和c-Raf…
E7080 (Lenvatinib)
E7080 (Lenvatinib)是一种多激酶抑制剂,可同时抑制VEGFR2和VEGFR3激酶。
XL647 (Tesevatinib)
XL647 (Tesevatinib)是一种口服生物可利用的小分子RTK抑制剂,可结合并抑制在肿瘤细胞增殖和肿瘤血管形成中…
ZM 306416
ZM 306416 hydrochloride是一种VEGF受体酪氨酸激酶抑制剂,可抑制KDR(IC50 = 100 nM)和Flt(IC50 = 2 uM)酪氨酸激酶…
NVP-BAW2881
NVP-BAW2881是有效的选择性VEGFR抑制剂(血管内皮生长因子受体酪氨酸激酶抑制剂),IC50 为值9 nM,具有抑制…
Toceranib (PHA 291639, SU 11654)
Toceranib (PHA 291639,SU 11654)是一种激酶抑制剂,通过抑制KIT,血管内皮生长因子受体2和PDGFRβ同时具有抗肿瘤…